Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Processa Pharmaceuticals Inc’s stock clocked out at $0.23, down -7.40% from its previous closing price of $0.25. In other words, the price has decreased by -$7.40 from its previous closing price. On the day, 0.63 million shares were traded. PCSA stock price reached its highest trading level at $0.2449 during the session, while it also had its lowest trading level at $0.2257.
Ratios:
To gain a deeper understanding of PCSA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.22 and its Current Ratio is at 1.22. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on April 25, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 27 ’25 when Yorke Justin W bought 12,400 shares for $0.80 per share. The transaction valued at 9,889 led to the insider holds 12,400 shares of the business.
Ng George K bought 87,200 shares of PCSA for $69,542 on Jan 27 ’25. The Chief Executive Officer now owns 87,200 shares after completing the transaction at $0.80 per share. On Jan 27 ’25, another insider, Young David, who serves as the Pres. Research & Development of the company, bought 124,500 shares for $0.80 each. As a result, the insider paid 99,289 and bolstered with 205,405 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCSA now has a Market Capitalization of 1220356 and an Enterprise Value of 102537.
Stock Price History:
The Beta on a monthly basis for PCSA is 1.33, which has changed by -0.9012766 over the last 52 weeks, in comparison to a change of 0.09765589 over the same period for the S&P500. Over the past 52 weeks, PCSA has reached a high of $3.10, while it has fallen to a 52-week low of $0.15. The 50-Day Moving Average of the stock is -37.67%, while the 200-Day Moving Average is calculated to be -76.26%.
Shares Statistics:
It appears that PCSA traded 2.26M shares on average per day over the past three months and 1997740 shares per day over the past ten days. A total of 5.27M shares are outstanding, with a floating share count of 4.63M. Insiders hold about 12.12% of the company’s shares, while institutions hold 1.88% stake in the company. Shares short for PCSA as of 1744675200 were 2014501 with a Short Ratio of 0.89, compared to 1741910400 on 95265. Therefore, it implies a Short% of Shares Outstanding of 2014501 and a Short% of Float of 42.66.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Processa Pharmaceuticals Inc (PCSA) is currently attracting attention from 1.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.65, with high estimates of -$0.65 and low estimates of -$0.65.
Analysts are recommending an EPS of between -$2.16 and -$2.16 for the fiscal current year, implying an average EPS of -$2.16.
